Mr. Baldry joined X4 in November 2022 as Chief Commercial Officer, bringing more than 30 years of international life science commercial experience to the role, with particular expertise in building high- performing commercial teams, developing effective global strategies, and launching new therapeutics into both specialty and rare disease markets.
Mr. Baldry previously served in the roles of Chief Commercial Officer at Freeline Therapeutics Holdings, Chief Commercial Officer at Wave Life Sciences, and Vice President, Global Marketing and then Senior Vice President, Global Marketing & Commercial Operations at Amicus Therapeutics. In these roles, he was responsible for building and executing on global commercial strategies to support successful launches of innovative medicines in orphan diseases, including the first oral chaperone therapy for the treatment of Fabry disease.
Throughout his earlier career, Mr. Baldry held multiple leadership positions at Biogen Inc., including Vice President, Public Affairs and Vice President, New Product Commercialization, and at the Human Genetic Therapies division of Shire Pharmaceuticals, where he served as Head of Global Strategic Marketing and Head of Marketing, Market Access, and Public Affairs, Europe, Middle East, and Africa. Mr. Baldry received a BSc in Genetics from York University (U.K.) and an MBA from Concordia University (Canada).
What is Mark Baldry's net worth?
The estimated net worth of Mark Baldry is at least $96.28 thousand as of May 16th, 2025. Mr. Baldry owns 25,337 shares of X4 Pharmaceuticals stock worth more than $96,281 as of December 5th. This net worth estimate does not reflect any other assets that Mr. Baldry may own. Learn More about Mark Baldry's net worth.
How old is Mark Baldry?
Mr. Baldry is currently 60 years old. There are 7 older executives and no younger executives at X4 Pharmaceuticals. The oldest executive at X4 Pharmaceuticals is Dr. Robert David Arbeit, Senior Vice President of Clinical Development and Translational Research, who is 76 years old. Learn More on Mark Baldry's age.
How do I contact Mark Baldry?
Has Mark Baldry been buying or selling shares of X4 Pharmaceuticals?
Mark Baldry has not been actively trading shares of X4 Pharmaceuticals in the last ninety days. Most recently, on Friday, May 16th, Mark Baldry bought 1,032 shares of X4 Pharmaceuticals stock. The stock was acquired at an average cost of $2.48 per share, with a total value of $2,559.36. Following the completion of the transaction, the insider now directly owns 25,337 shares of the company's stock, valued at $62,835.76. Learn More on Mark Baldry's trading history.
Who are X4 Pharmaceuticals' active insiders?
Are insiders buying or selling shares of X4 Pharmaceuticals?
During the last twelve months, X4 Pharmaceuticals insiders bought shares 2 times. They purchased a total of 87,238 shares worth more than $252,556.76. During the last twelve months, insiders at the sold shares 4 times. They sold a total of 6,753 shares worth more than $91,165.50. The most recent insider tranaction occured on October, 23rd when Chairman Adam R Craig bought 86,206 shares worth more than $249,997.40. Insiders at X4 Pharmaceuticals own 2.4% of the company.
Learn More about insider trades at X4 Pharmaceuticals. Information on this page was last updated on 10/23/2025.
